Last reviewed · How we verify
Moderate to Severe Alzheimer's Type Dementia
Approved treatments
- Donepezil (Aricept) · University of Virginia
- Aricept · Eisai Korea Inc.
- Namenda · Inova Health Care Services
- Namenda · AbbVie
Namenda works by blocking the action of glutamate at the NMDA receptor, reducing excessive neural activity associated with Alzheimer's disease. - Ebixa · Konkuk University Medical Center
- Aricept · Eisai
Aricept works by blocking the enzyme that breaks down a key neurotransmitter in the brain, acetylcholine.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Moderate to Severe Alzheimer's Type Dementia patent landscape — cliff calendar, originator estates, attackable patents
- Moderate to Severe Alzheimer's Type Dementia treatment landscape brief
- Moderate to Severe Alzheimer's Type Dementia treatment updates RSS
Frequently asked questions about Moderate to Severe Alzheimer's Type Dementia
What drugs treat Moderate to Severe Alzheimer's Type Dementia?
Tracked treatments include Donepezil (Aricept), Aricept, Namenda, Ebixa.
What is the treatment for Moderate to Severe Alzheimer's Type Dementia?
Standard treatment for Moderate to Severe Alzheimer's Type Dementia includes Donepezil (Aricept), Aricept, Namenda, Ebixa. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Moderate to Severe Alzheimer's Type Dementia patent cliff · Moderate to Severe Alzheimer's Type Dementia CI report
- Treatment: Donepezil (Aricept) · University of Virginia
- Treatment: Aricept · Eisai Korea Inc.
- Treatment: Namenda · Inova Health Care Services
- Treatment: Namenda · AbbVie
- Treatment: Ebixa · Konkuk University Medical Center
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing